OptimizeRx Co. (NASDAQ:OPRX) Receives $9.06 Consensus Target Price from Brokerages

OptimizeRx Co. (NASDAQ:OPRX) has received a consensus recommendation of “Moderate Buy” from the eleven analysts that are covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $10.38.

A number of research firms have weighed in on OPRX. Roth Capital reaffirmed a “buy” rating on shares of OptimizeRx in a research note on Tuesday. Citigroup restated an “outperform” rating on shares of OptimizeRx in a report on Tuesday. JMP Securities lifted their price target on OptimizeRx from $11.00 to $14.00 and gave the company a “market outperform” rating in a research note on Tuesday. Stifel Nicolaus boosted their price objective on OptimizeRx from $8.00 to $12.50 and gave the stock a “buy” rating in a report on Tuesday. Finally, B. Riley reissued a “buy” rating on shares of OptimizeRx in a research note on Tuesday.

Insiders Place Their Bets

In other news, Director James Paul Lang bought 321,408 shares of the company’s stock in a transaction on Friday, March 14th. The shares were purchased at an average price of $7.60 per share, with a total value of $2,442,700.80. Following the transaction, the director now directly owns 389,452 shares in the company, valued at $2,959,835.20. This represents a 472.35% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 6.10% of the stock is currently owned by insiders.

Institutional Trading of OptimizeRx

A number of institutional investors and hedge funds have recently modified their holdings of OPRX. SBI Securities Co. Ltd. bought a new position in OptimizeRx in the 4th quarter valued at $25,000. GAMMA Investing LLC bought a new position in OptimizeRx during the first quarter valued at about $33,000. SG Americas Securities LLC purchased a new stake in OptimizeRx during the fourth quarter worth about $51,000. Wells Fargo & Company MN raised its position in OptimizeRx by 33.3% in the fourth quarter. Wells Fargo & Company MN now owns 11,208 shares of the company’s stock worth $54,000 after acquiring an additional 2,797 shares during the period. Finally, Graham Capital Management L.P. purchased a new position in OptimizeRx in the fourth quarter valued at about $81,000. 76.47% of the stock is owned by hedge funds and other institutional investors.

OptimizeRx Stock Performance

Shares of OPRX opened at $10.11 on Thursday. OptimizeRx has a one year low of $3.78 and a one year high of $14.13. The company has a market cap of $186.96 million, a PE ratio of -7.60 and a beta of 1.28. The stock has a 50-day moving average of $8.46 and a 200-day moving average of $6.40. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.23 and a quick ratio of 3.23.

OptimizeRx (NASDAQ:OPRX) last issued its earnings results on Monday, May 12th. The company reported $0.08 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.19. OptimizeRx had a negative return on equity of 4.92% and a negative net margin of 27.41%. The company had revenue of $21.93 million for the quarter, compared to analyst estimates of $18.69 million. On average, equities research analysts predict that OptimizeRx will post -0.33 EPS for the current fiscal year.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.